Erectile dysfunction decisions — 2025

The Board granted service connection for tonsilitis and a left shoulder disability, but denied service connection for residuals of traumatic brain injury (TBI), right ankle, and left ankle disabilities. The claim for a higher rating for GERD was also denied.

The Board granted an effective date of March 2, 2023 for heart disease and September 28, 2023 for chronic renal failure, while denying earlier effective dates for PTSD, migraines, diabetes mellitus type II, hypertension, and bilateral hearing loss. The Board also granted a 70 percent evaluation for PTSD.

The Board remands the claims for service connection for a digestive disorder and erectile dysfunction (ED) to afford the Veteran VA examinations and obtain medical opinions addressing the etiology of his reported symptoms.

The Board denied service connection for erectile dysfunction, an increased rating for tinnitus, and a compensable rating for right hand trauma.

The Board remands the claims for service connection for hemorrhoids, colon polyps, and erectile dysfunction as additional medical opinions are required to address causation and aggravation.

The Board denied increased ratings for various service-connected conditions, including prostate cancer, left lung residuals, tinnitus, hearing loss, erectile dysfunction, and abdominal scar. Service connection was granted for headaches secondary to tinnitus.

The Board denied the veteran's claims for initial compensable ratings for erectile dysfunction, limitation of supination and pronation in both elbows.

The appeal for higher ratings and special monthly compensation was withdrawn by the Veteran before a decision was made.

The Board denied earlier effective dates for the grant of service connection for generalized anxiety disorder, migraine headaches, and special monthly compensation on account of loss of use of a creative organ.

The Board denied the Veteran's appeal for an earlier effective date of September 22, 2022, for service connection for erectile dysfunction and special monthly compensation based on loss of use of a creative organ.

All appeals for service connection and higher disability ratings were dismissed due to untimely Notices of Disagreement.

The Board remands the claims for service connection for various conditions, including erectile dysfunction, PTSD, depression, frequent urination, intermetatarsal neuroma right foot, left knee condition, right knee condition, low back strain, shoulder strain, and tinnitus, due to a failure to provide necessary examinations.

The Board denied service connection for a foot disability, heart disability, upper digestive disability, and erectile dysfunction as the evidence did not support a finding that these conditions were related to the Veteran's active military service.

The Board remands the claim for a medical opinion addressing whether the Veteran's service-connected bilateral tibial stress fractures aggravated his non-service-connected erectile dysfunction.

The Board granted service connection for erectile dysfunction, finding it to be caused by the Veteran's service-connected diabetes mellitus and hypertension.

The Veteran is granted special monthly compensation (SMC) at the rate provided by 38 U.S.C. §1114(l), effective March 9, 2021.

The Board granted service connection for pulmonary hypertension and erectile dysfunction as secondary to the Veteran's service-connected hypertension, but denied service connection for lead poisoning and carbon monoxide poisoning. The Board also denied a compensable initial disability rating for hypertension and an increased initial disability rating for lumbosacral strain.

The Board granted service connection for erectile dysfunction and low libido, finding that they were caused by the Veteran's service-connected psychiatric disability and the medication used to treat it.

The Board remands the appeal for additional development, including new medical examinations and opinions to address the claimed conditions.

The Board denied service connection for chronic sinusitis, hyperlipidemia, diabetes mellitus, type II, diabetic retinopathy, erectile dysfunction, kidney cancer, and coronary artery disease.